Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
André, Thierry, de Gramont, Armand, Vernerey, Dewi, Chibaudel, Benoist, Bonnetain, Franck, Tijeras-Raballand, Annemilaï, Scriva, Aurelie, Hickish, Tamas, Tabernero, Josep, Van Laethem, Jean Luc, Banzi, Maria, Maartense, Eduard, Shmueli, Einat, Carlsson, Goran U, Scheithauer, Werner, Papamichael, Demetris, Möehler, Marcus, Landolfi, Stefania, Demetter, Pieter, Colote, Soudhir, Tournigand, Christophe, Louvet, Christophe, Duval, Alex, Fléjou, Jean-François, de Gramont, Aimery
Published in Journal of clinical oncology (10.12.2015)
Published in Journal of clinical oncology (10.12.2015)
Get full text
Journal Article
Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study
Flejou, Jean-François, André, Thierry, Chibaudel, Benoist, Scriva, Aurelie, Hickish, Tamas, Tabernero, Josep, Van Laethem, Jean-Luc, Banzi, Maria, Maartense, Eduard, Shani, Adi, Carlsson, Göran, Scheithauer, Werner, Papamichael, Demetris, Moehler, Markus, Landolfi, Stefania, Demetter, Pieter, Duval, Alex, Lee, Mark, Colote, Soudhir, De Gramont, Aimery
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article